Discovery and development of broad spectrum anti-flaviviral drugs

描述（由申请人提供）：节肢动物传播的黄病毒引起广泛的重要人类疾病，对此没有特异性治疗方法。为了解决在应对这些新出现和重新出现的病毒的准备方面的严重不足，该提案的目标是发现新的药物靶点并开发可广泛用于治疗各种黄病毒感染的新的抗病毒疗法。四个独立的学术实验室，两个在杜克大学，两个在弗吉尼亚大学的合作伙伴关系，将攻击临床前药物开发的关键方面，组织成以下具体目标：（1）鉴定泛黄病毒治疗的高质量靶标。在这一目标中，三种独立但互补的方法将用于确定能够治疗不同黄病毒疾病的广谱疗法的细胞靶点。这些包括基因组规模的RNAi筛选，以确定黄病毒感染所需的新宿主因子，挖掘人类“嘌呤组”以找到支持感染的嘌呤结合蛋白，以及应用基于酵母的药物发现平台来识别新靶标。(2)黄病毒复制抑制剂的化学筛选。将评估目标1中确定的靶标，并使用蛋白质组挖掘和基于酵母的方法对一个子集进行小分子文库筛选。将优先考虑显示广谱活性的化合物，包括对蚊媒黄病毒的功效。(3)SAR和药物化学定义泛抗黄病毒抑制剂。多达六个独立的药物化学项目将根据Aim 2筛选出的最有吸引力的产品进行。先导化合物将针对体外结合效力和组织培养模型中的功效进行优化。(4)临床前测试。已建立的YFV和WNV感染的小鼠模型和新建立的DENV感染的模型将用于最大耐受剂量和初始药理学和功效研究。黄病毒是对美国公共卫生的新威胁，是我们的武装部队和部署在世界各地的其他公民的当前风险，也是全球的一个主要问题。在这个时候，几乎没有什么可以做的，以预防或治疗大多数黄病毒感染，因此开发广谱抗黄病毒药物是至关重要的。

DESCRIPTION (provided by applicant): Arthropod-borne flaviviruses cause a wide range of important human diseases for which there are no specific therapies. To address this critical shortfall in preparedness to confront these emerging and re-emerging viruses, the goal of this proposal is to discover novel drug targets and develop new antiviral therapies that can be used broadly to treat a variety of flaviviral infections. A partnership of four independent academic laboratories, two at Duke Univeristy and two at the University of Virginia, will attack crucial aspects of pre- clinical drug development, as organized into the following specific aims: (1) Identification of high-quality targets for pan-flaviviral therapeutics. In this aim, three independent yet complementary approaches will be used to identify cellular targets for broad-spectrum therapies capable of treating a diverse group of flaviviral illnesses. These include genome-scale RNAi screens to identify novel host factors required for flaviviral infection, mining of the human "purinome" to find purine-binding proteins that support infection, and application of a yeast-based drug discovery platform for the identification of novel targets. (2) Chemical screens for inhibitors of flavivirus replication. Targets identified in Aim 1 will be evaluated, and a subset will subjected to small molecule library screens using proteome mining and yeast-based methodologies. Priority will be given to compounds showing broad-spectrum activity including efficacy against mosquito-borne flaviviruses. (3) SAR and medicinal chemistry to define pan anti-flaviviral inhibitors. Up to six independent medicinal chemistry programs will be carried forward based on the most attractive products of the screens from Aim 2. Lead compounds will be optimized for potency of in vitro binding and efficacy in tissue culture models. (4) Pre-clinical testing. Established mouse models of YFV and WNV infection and newly established models of DENV infection will be used for maximum tolerated dose and initial pharmacological and efficacy studies. Flaviviruses are an emerging threat to public health in the US, a current risk to our armed forces and other citizens deployed around the world, and a major problem globally. At this time there is little that can be done to prevent or treat the majority of flaviviral infections and therefore development of broad-spectrum anti-flaviviral drugs is of crucial importance.